Penn Virginia (PVA) – Press Releases
-
pSivida Corp. Builds Momentum During First Quarter FY18; Continues Operating Milestone Execution
-
pSivida Corp. Announces First Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Information
-
pSivida and Nicox Enter Strategic Collaboration Agreement to Develop Sustained Release Drug to Lower Intraocular Pressure in Patients with Glaucoma
-
pSivida Partners with Global Pharmaceuticals Company to Develop Sustained Release Formulations of Glaucoma Drugs
-
pSivida to Present at the Ladenburg Thalmann 2017 Healthcare Conference
-
pSivida Corp. Achieves Significant Milestones Throughout FY 2017; Reports Fourth Quarter and Fiscal 2017 Results
-
pSivida to Present at Rodman & Renshaw Annual Global Investment Conference
-
pSivida Corp. to Report Fourth Quarter and Fiscal Year 2017 Financial Results on Monday, September 11th
-
pSivida to Present at Canaccord Genuity Growth Conference on August 10, 2017
-
Leading Retinal Specialists to Highlight pSivida’s Durasert for Treatment of Posterior Segment Uveitis at Prestigious Ophthalmology Conferences
-
pSivida Out-licenses EMEA Rights for Durasert™ Three-year Treatment for Posterior Segment Uveitis While Retaining U.S. Commercial Rights; Amended Global Collaboration Agreement with Alimera for ILUV
-
pSivida Enhances Board of Directors with Election of Veteran Healthcare Executive Kristine Peterson
-
pSivida Submits Marketing Authorization Application (MAA) for Approval of Durasert™ Three-year Treatment for Posterior Segment Uveitis in the European Union
-
pSivida’s Durasert™ Three-year Treatment for Posterior Segment Uveitis Successfully Achieves Primary Efficacy Endpoint in Second Phase 3 Study
-
Durasert™ Three-year Treatment for Posterior Segment Uveitis Significantly Reduces Recurrences Through 12 Months
-
pSivida Corp. Reports Fiscal 2017 Third Quarter Results; Key Milestones on Track
-
pSivida Corp. to Report Third Quarter Fiscal Year 2017 Financial Results on Thursday, May 4th
-
Abstract on pSivida's Treatment of Posterior Segment Uveitis Accepted for Presentation at the 2017 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
-
pSivida to Present at the 2017 BIO CEO & Investor Conference
-
pSivida Corp. Reports Fiscal 2017 Second Quarter and First Half Results
-
pSivida Corp. Announces Second Quarter Fiscal Year 2017 Financial Results Release Date and Conference Call Information
-
Seasoned Ophthalmology Executive Deb Jorn Joins pSivida to Focus on Corporate and Commercial Development
-
pSivida Corp. Reports Fiscal 2017 First Quarter Results and Provides Update on Corporate Objectives & Milestone Timeline
-
pSivida Corp. Announces First Quarter Fiscal Year 2017 Financial Results Release Date and Conference Call Information
-
Phase 3 trial of Medidur™ in Posterior Segment Uveitis Meets Enrollment Target
-
pSivida Corp. Strengthens Board of Directors With Leading Ophthalmologist
-
pSivida to Present at the Ladenburg Thalmann Annual Healthcare Conference
-
pSivida Reports Inducement Awards to New President and Chief Executive Officer
-
pSivida Implements Leadership Change -- Nancy Lurker Named as President and CEO
-
pSivida Corp. Provides Company Update and Reports Fourth Quarter and FY 2016 Results
-
pSivida Corp. Announces Fourth Quarter and Fiscal Year 2016 Financial Results Release Date and Conference Call Information
-
pSivida Announces 13 New Patents Issued or Allowed
-
Topline Results from First Phase 3 Trial of pSivida’s Medidur™ Presented at ASRS Annual Meeting
-
Primary Endpoint Met in pSivida’s Utilization Study of New Medidur™ Inserter with Smaller Diameter Needle
-
pSivida Names Dario Paggiarino, M.D. as Chief Medical Officer
-
pSivida Corp and Hospital for Special Surgery Innovation Center Announce Opening of IND for Sustained-Release Implant for Severe Knee Osteoarthritis
-
pSivida's Medidur™ Maintains Same High Statistical Significance in Primary Endpoint through 12 Months in First Phase 3 Trial (p Less Than 0.00000001)
-
Data Shows pSivida’s Tethadur™ Provides Prolonged, Sustained Release of Avastin® With High Drug Efficacy
-
pSivida Corp. Announces Plan to Consolidate all Research and Development in Current U.S. Facility
-
Investigator-Sponsored Phase 2 Study Results Show pSivida’s Medidur® Fully Controlled Uveitis for Two Years with No Recurrence of Disease While Visual Acuity Continued to Improve
-
pSivida Announces Poster and Oral Presentation on Controlled Release of Avastin® from Tethadur™ Biodegradable Matrix at the 2016 Controlled Release Society Annual Meeting
-
pSivida Announces Successful Completion of Two Preclinical Studies of Durasert™ Sustained-Release Insert Delivering Repurposed Cancer Drug to Treat Wet AMD
-
pSivida Corp. Provides Company Update and Reports Third Quarter FY 2016 Results
-
pSivida CEO to Present at 2016 International Symposium of Ocular Pharmacology and Therapeutics
-
pSivida’s Medidur for Posterior Uveitis Granted Orphan Drug Designation in Europe
-
pSivida Corp. Announces Third Quarter Fiscal Year 2016 Financial Results Release Date and Conference Call Information
-
pSivida to Present at the Sidoti Spring 2016 Emerging Growth Convention
-
Additional Favorable Six-Month Safety Results for pSivida's Medidur™ for Posterior Uveitis
-
pSivida Corp. Provides Company Update and Reports Second Quarter FY 2016 Results
-
pSivida Corp Announces Second Quarter Fiscal Year 2016 Financial Results Release Date and Conference Call Information
Back to PVA Stock Lookup
